Briefs: BDR Pharma seeks Sprycel compulsory license; Hospira gains Precedex extension; Perrigo to start shipping generic Mucinex

18 March 2013

Indian generic drugmaker BDR Pharmaceuticals has applied to India's patent office for a compulsory licence to sell a generic version of Bristol-Myers Squibb (NYSE: BMY) leukemia drug Sprycel (dasatinib) under a global Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement, a BDR executive said on Monday, reports Reuters.

The Indian government announced earlier this year that it is considering compulsory licensing of more cancer drugs, having done so for Bayer’s kidney cancer treatment Nexavar (sorafenib), including Roche’s Herceptin (trastuzumab) and B-MS’s Ixempra (ixabepilone) and Sprycel (The Pharma Letter January 15). Bayer recently lost its appeal in the Nexavar final appeals court decision (TPL March 5).

Hospira obtains six months US pediatric exclusivity for Precedex injection

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK